Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImageMelTherapyLRI

Financiado

Cerrado

Single cell level intravital imaging of response tolerance and resistance to t...

Single cell level intravital imaging of response tolerance and resistance to targeted therapies Oncogenic signalling by kinases presents a significant opportunity for cancer therapy. The B-Raf selective inhibitor, Vemurafenib, has shown great effect against B-Raf mutant melanoma patients. However, drug resistance emerges in... ver más

30/06/2015

The Francis Crick...

231K€

Presupuesto del proyecto: 231K€

Líder del proyecto

THE FRANCIS CRICK INSTITUTE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-06-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

The Francis Crick Institute

0.00€ | Lider

CR-UK

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NOSCAR decipheriNg Oncogenic SIgnalling patterns to break CAncer dr... 305K€ Cerrado

MODSIGN Modification of receptor tyrosine kinase signalling during t... 100K€ Cerrado

PDC2022-133569-I00 DESARROLLO DE UN BIOMARCADOR DE LA RESPUESTA TERAPEUTICA DEL... 150K€ Cerrado

SAF2015-63638-R PROTEINAS SCAFFOLD COMO MODULADORES DE LA RESISTENCIA A INHI... 472K€ Cerrado

CROC The natural K, Fe, and Cu isotopic response to Pt-based chem... 176K€ Cerrado

3DTUMOUR Development of a high throughput microplate based device to... 150K€ Cerrado

Líder del proyecto

THE FRANCIS CRICK INSTITUTE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 231K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Oncogenic signalling by kinases presents a significant opportunity for cancer therapy. The B-Raf selective inhibitor, Vemurafenib, has shown great effect against B-Raf mutant melanoma patients. However, drug resistance emerges in nearly every case. Various mechanisms underlying this resistance are described, however these approaches usually overlook the heterogeneity of the tumour microenvironment, and do not provide information about the temporal aspects of drug response and eventual emergence of resistance. Therefore, uncovering the spatio-temporal heterogeneity, i.e., when, where, and how melanoma cells respond to drug and acquire resistance in a complex tumour microenvironment is the key step toward the comprehensive understanding of resistance mechanisms. To tackle these problems, we will investigate the tolerance and resistance to B-Raf inhibitors with single cell resolution in vivo. We have established melanoma cell lines stably expressing EKAR-EV biosensor that reports ERK activity in living cells. In vitro, the melanoma cells show homogenous responses to BRaf inhibitors, whereas intravital analysis indicate that there is considerable heterogeneity in ERK activity within tumours. This cannot be attributed simply B-Raf mutation as all cells contain the oncogene, and we hypothesize that additional signals from the microenvironment activate ERK, possibly putting the neighbouring melanoma cells in drug-tolerant state. Similar mechanisms are possible at metastatic locations. The tumour microenvironment of CNS metastases is quite different from those of other organs, it is particularly enriched in RTK ligands. In the longer term, we will study how metastatic melanoma cells may respond to and tolerate the drugs in the CNS. In summary we aim to identify the micro-environmental signals that activate ERK, and explore how these signals may confer tolerant to BRaf inhibition and ultimately aid the emergence of drug resistant clones.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores